Ingrid Hedenfalk
11 – 20 of 93
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Detection of Copy Number Aberration and Tumor Fraction in Archival Cervical Specimens from Ovarian Cancer Patients using Shallow Whole Genome Sequencing.
2021)(
- Contribution to conference › Poster
-
Mark
MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer
(
- Contribution to journal › Article
-
Mark
Evaluation of multiple transcriptomic gene risk signatures in male breast cancer
(
- Contribution to journal › Article
-
Mark
Common Susceptibility Loci for Male Breast Cancer
(
- Contribution to journal › Article
-
Mark
Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer
(
- Contribution to journal › Article
- 2020
-
Mark
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer
(
- Contribution to journal › Article
-
Mark
Simvastatin is a potential candidate drug in ovarian clear cell carcinomas
(
- Contribution to journal › Article
-
Mark
A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients
(
- Contribution to journal › Article
-
Mark
SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery
(
- Contribution to journal › Article
-
Mark
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
(
- Contribution to journal › Article